For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

MECC HN01 - HPV De-escalated Protocol

Trial Overview

Official Title

De-escalation Protocol of HPV Mediated Oropharyngeal Squamous Cell Carcinoma Based on the American Joint Committee on Cancer Care (AJCC) 8th Edition Staging Manual

Study Purpose

HPV positive head and neck cancer has been shown to respond very well to treatment and, as a result, the head and neck cancer staging system was updated to better reflect how HPV cancers respond to treatment.  The purpose of this study is to evaluate the effects of treating patients with Human Papilloma Virus (HPV) positive head and neck cancer with less treatment based on the updated head and neck cancer staging system.

Diagnosis

HPV positive Squamous Cell Carcinoma of the tonsils, base of tongue, or oropharyngeal cavity

Eligibility

Must have HPV positive head and neck cancer.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Treatments on this study can involve surgery, radiation or chemotherapy.  May receive just one of those treatments or a combination of treatments based on the stage of the disease.  This will be determined by your doctor and the Nebraska Methodist Multidisciplinary Tumor Board.
  • Study agents: Cisplatin
  • Quality of Life questionnaires
Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Not Applicable